Hikma Pharmaceuticals PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HKMPY research report →
About the company
Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products.
- CEO
- Said Samih Taleb Darwazah
- IPO
- 2012
- Employees
- 9,500
- HQ
- London, GB
Price Chart
- Market Cap
- $4.34B
- P/E
- 0.19
- P/S
- 1.30
- P/B
- 1.75
- EV/EBITDA
- 8.40
- Div Yield
- 3.99%
- Gross Margin
- 41.35%
- Op Margin
- 16.81%
- Net Margin
- 12.00%
- ROE
- 15.83%
- ROIC
- 10.21%
- Revenue
- $3.36B · 7.35%
- Net Income
- $402.94M · 12.24%
- EPS
- $3.66 · 12.96%
- Op Income
- $569.33M
- FCF YoY
- -50.64%
- 52W High
- $55.33
- 52W Low
- $31.80
- 50D MA
- $39.19
- 200D MA
- $40.91
- Beta
- 0.65
- Avg Volume
- 174
Get TickerSpark's AI analysis on HKMPY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HKMPY coverage
Recent articles, reports, and earnings notes.
No research on HKMPY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HKMPY report →Similar companies
Peers in the same neighborhood.